Stockreport

Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update

Foghorn Therapeutics Inc.  (FHTX) 
PDF - FHD-286 Phase 1 dose escalation study in metastatic uveal melanoma continues to progress with initial data expected in the first half of 2023 - FHD-609 Phase 1 pharma [Read more]